What the Latest Research Really Says About Mushrooms and Health

For years, the conversation around functional mushrooms ran well ahead of the science. Laboratory studies produced intriguing findings, traditional use supplied compelling stories and supplement marketing filled the space between the two with promises that were often far more certain than the evidence allowed.

That gap is beginning to narrow. Researchers are now moving beyond cells and animal models into controlled human studies, examining not simply whether mushroom compounds can do something in theory, but whether eating a particular mushroom, in a particular form and quantity, produces a measurable effect in real people.

The emerging picture is more interesting than the usual list of miracle benefits, and considerably more nuanced. There are encouraging signals around memory, mood, metabolic health and immune regulation. There are also well-designed studies that have found little or no effect. That is not a weakness in the research. It is how reliable knowledge is built.

Perhaps the most important lesson is that ‘mushrooms’ cannot be treated as a single ingredient. Oyster mushroom, Lion’s Mane, Tremella and Reishi contain different compounds, are prepared in different ways and are being studied for different reasons. A culinary portion of oyster mushrooms is not equivalent to a concentrated Lion’s Mane extract, just as an orange is not interchangeable with a vitamin C tablet.

The most compelling new evidence concerns the ageing brain

One of the most interesting recent studies was published in May 2026. Researchers recruited 80 healthy adults between the ages of 60 and 80 and asked them to consume four portions of oyster mushrooms each week for 12 weeks. A comparison group received a placebo food.

At the end of the study, the oyster mushroom group performed better on tests of delayed word recall and recognition. They also reported lower anxiety and less negative mood than the placebo group. The researchers concluded that the intervention appeared to maintain mood and improve episodic memory over the 12-week period.

This is notable because the participants ate an ordinary edible mushroom rather than swallowing a highly concentrated experimental compound. It begins to answer a more practical question: can mushrooms consumed as food make a measurable difference?

The answer, in this study, was a cautious yes. However, it was still a relatively small and short trial. Some of the researchers’ inflammation work was also conducted in a laboratory cell model rather than directly in the participants, so it would be premature to say that oyster mushrooms have been shown to reduce inflammation in the human brain. The cognitive and mood findings are promising, but they now need to be repeated in larger and more diverse groups. Read the 2026 oyster mushroom trial.

A second study published in 2026 approached the question from a different direction. Researchers followed 3,162 middle-aged and older Japanese adults for an average of more than ten years. Mushroom intake was recorded through detailed food diaries, while short-term and working memory were assessed using forward and reverse number-recall tests.

People with higher mushroom consumption tended to perform better on both memory measures, with the strongest associations appearing at moderate to higher levels of intake. The long follow-up and large group make the findings interesting, but they do not prove that mushrooms caused the difference. People who eat more mushrooms may also have healthier diets, different incomes or other lifestyle advantages that are difficult to remove completely from an observational study. Read the Japanese longitudinal study.

These findings sit alongside a 2024 analysis of the large EPIC-Norfolk cohort in Britain, which also found an association between mushroom consumption and stronger performance across several cognitive measures. Once again, this was an observational finding rather than a clinical trial, but it adds to a pattern that is becoming difficult to ignore. Read the EPIC-Norfolk study.

One possible reason for this interest is ergothioneine, a naturally occurring compound found particularly abundantly in mushrooms. The human body has a dedicated transporter for ergothioneine, and lower blood levels have been associated with cognitive impairment and neurodegenerative disease. That does not yet establish ergothioneine as a treatment, but it offers researchers a plausible biological route through which mushrooms might influence healthy ageing.

Lion’s Mane remains promising, but the verdict is far from settled

No mushroom has attracted more attention for cognition than Lion’s Mane. Its distinctive appearance and compounds known as hericenones and erinacines have made it a favourite of the supplement industry. Yet the human evidence remains a mixture of encouraging findings, small studies and unanswered questions.

In a 2023 randomised, double-blind trial, 41 healthy adults aged between 18 and 45 received either 1.8 grams of Lion’s Mane or a placebo. The researchers examined both the effect of a single dose and daily use over 28 days.

After the first dose, the Lion’s Mane group completed one attention-related task more quickly. After four weeks, there was also a near-significant trend towards lower perceived stress. However, many of the other cognitive and mood measures showed no meaningful advantage, and the researchers were explicit that the small sample made firm conclusions impossible. Read the 2023 Lion’s Mane trial.

A further double-blind study published in 2025 produced an even more restrained result. Eighteen healthy young adults received a single dose of a concentrated Lion’s Mane fruiting-body extract. The researchers found no significant overall improvement in cognition or mood compared with placebo. Participants did perform better on one test of fine motor dexterity, but the broader cognitive findings were negative. Read the 2025 acute Lion’s Mane study.

These studies do not show that Lion’s Mane is ineffective. They show that the familiar claim that it simply ‘improves focus and memory’ is too broad. An acute dose may behave differently from months of regular use. A fruiting-body powder may not be equivalent to a mycelial extract. Healthy adults may respond differently from people already experiencing cognitive decline.

The most honest conclusion is that Lion’s Mane deserves further study, particularly in longer trials with larger groups and clearly characterised products. It is an intriguing subject of research, not a proven substitute for sleep, exercise, medical care or a healthy diet.

Mushrooms may influence metabolism in ways we are only beginning to understand

Brain health receives much of the attention, but some of the more unusual recent findings have concerned blood sugar and body composition.

In a 2024 double-blind trial, 56 adults who were overweight or living with obesity and prediabetes received either a daily drink containing Tremella fuciformis, commonly called snow mushroom, or a placebo for 12 weeks.

The Tremella group experienced a small reduction in glycated haemoglobin, or HbA1c, from 6.03% to 5.96%. Their average waist circumference also fell from 95.2 centimetres to 93.46 centimetres. No adverse events were reported.

These are modest changes, and the study was exploratory. The reduction in HbA1c was not large enough to establish Tremella as a treatment for prediabetes, while the sample was too small to know how widely the result would apply. It nevertheless provides an interesting early indication that mushroom-derived beta-glucans may have metabolic effects worth investigating in larger trials. Read the Tremella trial.

The broader cardiometabolic picture is less dramatic. In a controlled 2024 feeding study, adults followed a healthy Mediterranean-style diet either with or without approximately 84 grams of white button and oyster mushrooms each day. Both groups showed some improvements, but adding mushrooms did not meaningfully improve most cardiometabolic risk markers beyond the effect of the healthy diet itself.

That finding is worth taking seriously. It suggests mushrooms may be most valuable as part of a good dietary pattern rather than as a corrective ingredient sprinkled on top of an otherwise poor diet. They can contribute fibre, flavour and a range of nutrients while replacing foods higher in saturated fat, salt or energy. That ordinary culinary role may ultimately prove more important than any headline-grabbing ‘superfood’ effect.

Reishi research is replacing the language of ‘immune boosting’ with something more precise

The phrase ‘boosts immunity’ is used so casually that it has almost ceased to mean anything. The immune system is not a single dial that should always be turned upwards. A healthy response requires activation when necessary, restraint when the threat has passed and balance between multiple types of immune cell.

A 2024 double-blind study of Reishi, or Ganoderma lucidum, offers a more sophisticated way of looking at the subject. Sixty older women initially entered the study, although 39 completed it. Participants received either two grams of Reishi dry extract per day or a placebo for eight weeks.

The researchers observed changes in T-lymphocyte behaviour and gene expression, including a reduction in the proportion of inflammatory Th17 cells and changes associated with regulatory and anti-inflammatory immune activity. The result suggests that Reishi may modulate aspects of immune function rather than simply making the immune system ‘stronger’.

Crucially, the study measured laboratory immune markers. It did not show that participants caught fewer infections, recovered more quickly or experienced better long-term health. Those clinical questions remain unanswered. Read the 2024 Reishi study.

This distinction matters. An interesting shift in immune cells is a reason for further research, not proof that a product prevents colds, treats inflammation or protects against disease.

Vitamin D mushrooms reveal why negative results matter

Mushrooms have another unusual characteristic: when exposed to ultraviolet light, they can convert naturally occurring ergosterol into vitamin D2. This has led to interest in UV-treated mushrooms as a food-based source of vitamin D, particularly during darker months.

A 2026 randomised trial tested that idea in 41 adults who were overweight or living with class I obesity. Participants in the mushroom group were asked to eat 168 grams of UV-exposed cremini mushrooms each day over six winter weeks. The mushrooms were intended to provide 800 IU of vitamin D2 daily.

Blood levels of vitamin D2 increased. However, total vitamin D status still declined because vitamin D3 levels fell, and the decline was not significantly different from the control group. Testing also revealed a practical problem: only 67% of the mushroom samples actually contained the expected vitamin D2.

The study does not mean that vitamin D-enriched mushrooms have no nutritional value. It shows that their performance depends on reliable UV exposure, consistent production and the way vitamin D2 behaves in the body. In this population, they did not prevent the seasonal fall in total vitamin D status. Read the 2026 vitamin D mushroom trial.

It is a useful example of science doing its job. A plausible idea was tested under real conditions, and the result was more complicated than expected. That knowledge is far more valuable than another unqualified claim that mushrooms are ‘high in vitamin D’.

So, what can we reasonably say?

The recent research is genuinely encouraging, particularly around cognitive ageing. The 2026 oyster mushroom trial is among the strongest new signals because it used a controlled intervention, an ordinary edible mushroom and recognisable outcomes such as delayed memory and mood. Long-term observational studies in Japan and Britain point in a similar direction.

Lion’s Mane remains scientifically interesting, but results in healthy adults have been mixed and the studies are still small. Tremella has produced an early metabolic signal in people with prediabetes, while Reishi appears capable of influencing immune-cell behaviour. Neither finding should be translated into a promise to treat diabetes, inflammation or infection.

The wider lesson is that species, preparation and dose matter. Fruiting body and mycelium are not automatically interchangeable. Whole powder and concentrated extract are not the same material. Results obtained with one mushroom cannot simply be transferred to every mushroom blend on the market.

Mushrooms are nutritious foods with distinctive fibres, antioxidants and bioactive compounds. They are also the subject of a rapidly developing field of human research. What they are not is a universal cure disguised as a kitchen ingredient.

The science is becoming more persuasive precisely because it is becoming more careful. Some trials find benefits. Others find none. Together they are replacing exaggerated certainty with something much more useful: a clearer understanding of which mushrooms may help, in what form, for whom and under what conditions.

For a simple way to put the research into everyday practice, Mush Mór offers three distinct approaches. Original provides the whole-food character of seven mushroom powders, retaining their natural fibre, protein and broader nutritional profile. Adaptive Extracts brings together ten concentrated mushroom extracts in a format designed for coffee, tea and other daily drinks. Lion’s Mane offers a single-mushroom option with a deeper savoury flavour for broths, sauces and cooking. Together, the range combines the nutritional value and culinary versatility of whole mushroom powders with the convenience and concentration of extracts.